579 related articles for article (PubMed ID: 36103744)
21. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.
Chowdhury T; Roymahapatra G; Mandal SM
Infect Disord Drug Targets; 2021; 21(4):608-618. PubMed ID: 32718300
[TBL] [Abstract][Full Text] [Related]
22. An In silico Investigation to Identify Promising Inhibitors for SARS-CoV-2 M
Alagarsamy V; Sundar PS; Narendhar B; Sulthana MT; Kulkarni VS; Aishwarya AD; Solomon VR; Murugesan S; Jubie S; Rohitha K; Dhanwar S
Med Chem; 2023; 19(9):925-938. PubMed ID: 37069723
[TBL] [Abstract][Full Text] [Related]
23. Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an
Amin M; Abbas G
J Biomol Struct Dyn; 2021 Aug; 39(12):4243-4255. PubMed ID: 32469265
[TBL] [Abstract][Full Text] [Related]
24. Targeting SARS-CoV-2 nucleocapsid oligomerization: Insights from molecular docking and molecular dynamics simulations.
Ahamad S; Gupta D; Kumar V
J Biomol Struct Dyn; 2022 Apr; 40(6):2430-2443. PubMed ID: 33140703
[TBL] [Abstract][Full Text] [Related]
25. Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identification of potential SARSCOV-2 inhibitors.
Boadu A; Agoni C; Karpoormath R; Soliman M; Nlooto M
Sci Rep; 2022 Jun; 12(1):10896. PubMed ID: 35764663
[TBL] [Abstract][Full Text] [Related]
26. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
27. Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD.
Chauhan A; Avti P; Shekhar N; Prajapat M; Sarma P; Bhattacharyya A; Kumar S; Kaur H; Prakash A; Medhi B
Comput Biol Med; 2021 Jul; 134():104495. PubMed ID: 34022485
[TBL] [Abstract][Full Text] [Related]
28. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
[TBL] [Abstract][Full Text] [Related]
29. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.
Ahmad S; Waheed Y; Ismail S; Bhatti S; Abbasi SW; Muhammad K
Molecules; 2021 Mar; 26(5):. PubMed ID: 33800013
[TBL] [Abstract][Full Text] [Related]
30. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.
Mishra CB; Pandey P; Sharma RD; Malik MZ; Mongre RK; Lynn AM; Prasad R; Jeon R; Prakash A
Brief Bioinform; 2021 Mar; 22(2):1346-1360. PubMed ID: 33386025
[TBL] [Abstract][Full Text] [Related]
31. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
32. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
33. Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, M
Naidoo D; Kar P; Roy A; Mutanda T; Bwapwa J; Sen A; Anandraj A
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500548
[TBL] [Abstract][Full Text] [Related]
34. Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.
Tatar G; Ozyurt E; Turhan K
Biotechnol Prog; 2021 Mar; 37(2):e3110. PubMed ID: 33314794
[TBL] [Abstract][Full Text] [Related]
35. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
36. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
[TBL] [Abstract][Full Text] [Related]
37. In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.
Zhang C; Liu J; Sui Y; Liu S; Yang M
Sci Rep; 2023 Dec; 13(1):21404. PubMed ID: 38049492
[TBL] [Abstract][Full Text] [Related]
38. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
[TBL] [Abstract][Full Text] [Related]
39. Tetracycline as an inhibitor to the SARS-CoV-2.
Zhao TY; Patankar NA
J Cell Biochem; 2021 Jul; 122(7):752-759. PubMed ID: 33619758
[TBL] [Abstract][Full Text] [Related]
40. Virtual Screening of
Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
